Loader
We have noticed an unusual activity from your IP 199.16.157.182 and blocked access to this
We have noticed an unusual activity from your IP 199.16.157.182 and blocked access to this
The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.
Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.
Axel Hauschild, MD, elucidates the varying role of treatment for both cutaneous cell carcinoma and basal cell carcinoma that are seen globally.
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Is vaping a better option if you’re trying to quit smoking? An @OSUCCC_James expert breaks down the health risks of cigarettes and e-cigarettes.
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Melanoma is often detected later in people with darker skin complexions and the consequences can be devastating, a Mayo Clinic study reveals.
CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.
An abstract is unavailable.
Dyikanov et al. developed a machine learning platform that uses a simple blood test to reveal cellular compositions reflective of a person’s immune system. These compositions,…